Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib versus hydroxychloroquine for cutaneous lichen planus
IRCT20241025063490N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-blind trial of baricitinib in Cutaneous Lichen Planus (CLP) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Severity of pruritis. Started Jan 2025; status: completed.
02
Drugs
baricitinib
03
Conditions
Cutaneous Lichen Planus (CLP)
Beyond the preview
Go deeper on IRCT20241025063490N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241025063490N1.